He speculated that there could be more uses for omalizumab. “In this study, we looked at the most sensitive patients, but perhaps this drug could have a significant impact on patients with a more mild form of sensitivity,” Dr. Hong said. “Maybe [omalizumab] could take the place of desensitization for patients with a milder sensitivity – we don’t know.”
Dr. Hong reports no relevant financial disclosures. Novartis Pharmaceuticals funded this research and provided omalizumab.
SOURCE: Hong DI et al. AAAAI/WAO Joint Congress, Poster L33.